https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25283 Sat 24 Mar 2018 07:38:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46198 2 days 1 to 3, and etoposide 80 mg/m² days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.]]> Mon 14 Nov 2022 11:22:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54830 Fri 15 Mar 2024 11:53:47 AEDT ]]>